Posted On: Wednesday, January 14th, 2015
Pacific Hepatitis C Network’s Annual General Meeting is taking place Monday, January 26, 3 – 5 pm. This AGM is our first completely online AGM and we are looking forward to having as many of you attending as possible! It has been hard to have full participation in the past because our PHCN members –… Read more »
Posted On: Friday, January 9th, 2015
January Updates Community of Practice: If you haven’t had a chance to join in our Community of Practice, then now is the time to start some new trends. The CoP is a community of frontline workers across the province who are interested in Mental Health and Substance Use. This is a forum to share your… Read more »
Posted On: Wednesday, January 7th, 2015
Please note: HepCBC wants to clarify that the “speculative price” in Canada for AbbVie’s interferon-free HolkiraTM Pak given on page 3 of our January, 2015 Bulletin is not official, and doesn’t reflect any real pricing. We can say that on or before January 16th, we will be able to post the actual price on our… Read more »
Posted On: Wednesday, January 7th, 2015
Response to Treatment by Prevention Article The Globe and Mail article: B.C. medical researchers offer treatment by prevention for hepatitis C PHCN recognizes treatment as prevention (TasP) as the strategy of choice for people who use injection/inhalation drugs, who, as a group, have the highest rate of new HCV infections. Treatment as prevention is an… Read more »
Posted On: Wednesday, January 7th, 2015
New and Noteworthy: Telaprevir discontinued in Canada Telaprevir (Incivek) has been discontinued in Canada as of January 1, 2015. Telaprevir is a first generation direct-acting anti-viral medication that is used in combination with peg-interferon and ribavirin to treat hepatitis C. The availability of new treatments for hepatitis C has resulted in a decreased demand for… Read more »
Posted On: Wednesday, December 17th, 2014
New and Noteworthy Harvoni cures 98% of Hep C and HIV co-infected participants with genotype 1 virus 98% of Hep C and HIV co-infected participants with genotype 1 virus who took Harvoni (ledipasvir + sofosbuvir) during a 12-week clinical trial were cured, reported researchers at the American Association for the Study of Liver Diseases (AASLD)… Read more »
Posted On: Wednesday, December 10th, 2014
Before reading this newsletter, HepCBC is asking for you and your friends to help make hepatitis C drugs more accessible and affordable. You can do so by answering a few simple questions to help HepCBC make a great Patient group Input submission to CADTH (Canadian Agency for Drugs and Technologies in Health) about the value… Read more »
Posted On: Wednesday, December 3rd, 2014
New and Noteworthy Harvoni (ledipasvir + sofosbuvir) approved by Health Canada In October, Health Canada approved the hepatitis C medication Harvoni (ledipasvir + sofosbuvir) for people over the age of 18 with genotype 1 hepatitis C virus. In clinical trials, the cure rate for this combination was 94% to 100%. Ledipasvir and sofosbuvir are both… Read more »
Posted On: Thursday, November 27th, 2014
The PHCN’s Hepatitis C Treatment Information Project was recently updated. New sections and pages were added to accommodate the ever growing wealth of information that the project now includes. For example, check out the newly rearranged Hep C Drug Pipeline page, which summarizes the treatments that are currently making their way through the hep C… Read more »
Posted On: Wednesday, November 19th, 2014
Posted On: Thursday, November 13th, 2014
Survey participants with hep C or living with/caring for someone with hep C needed immediately! Take this survey! The Canadian Agency for Drugs and Technologies in Health (CADTH) is currently seeking patient group input reports for ombitasvir / paritaprevir / ritonavir and dasabuvir, developed by AbbVie. Thus, Pacific Hepatitis C Network (PHCN) needs your help… Read more »
Posted On: Thursday, November 6th, 2014
New and Noteworthy Interactions with transplant drugs added to simeprevir product monograph The U.S. Food and Drug Administration (FDA) recently approved revisions to the product label information for the direct-acting anti-viral medication simeprevir, known by the brand name Galexos in Canada. The revisions highlighted drug interactions with cyclosporine and tacrolimus, which are used to prevent… Read more »
